CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Camp4 Therapeutics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$3.14−0.03 (-0.95%)
Close on Oct 19, 2026
- Market cap
- $181.90M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$0.21 (+7.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Camp4 Therapeutics Corp grew revenue 40.2% to $4.22M over the twelve months to Jun 30, 2026. Free cash flow was -$28.72M.
Revenue
$4.22M
+40.2% vs. a year earlier
Operating income
-$52.88M
TTM Q2 2026
Free cash flow
-$28.72M
TTM Q2 2026
EPS, diluted
-$2.20
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $181.90M
- P/E ratio
- –
- Price to sales
- 43.14
- Price to book
- –
- Dividend yield
- 0.00%
- Free cash flow yield
- -15.79%
Fundamentals
- Revenue
- $4.22M
- Net income
- -$107.24M
- EPS, diluted
- -$2.20
- Free cash flow
- -$28.72M
- Book value per share
- -$0.01
- Diluted shares
- 58M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$4.22M+40.2% YoY
Operating income
-$52.88M
Net income
-$107.24M
EPS, diluted
-$2.20
Free cash flow
-$28.72M
Reported periodTrailing twelve months